Cargando…
Dural Immune Cells, CGRP, and Migraine
Migraine is the most common neurological disorder in the world, affecting 12% of the population. Migraine involves the central nervous system, trigeminal nerves and meninges. Recent advances have shown that targeting calcitonin gene-related peptide (CGRP) through either antibodies or small molecule...
Autores principales: | Balcziak, Louis K., Russo, Andrew F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9009415/ https://www.ncbi.nlm.nih.gov/pubmed/35432179 http://dx.doi.org/10.3389/fneur.2022.874193 |
Ejemplares similares
-
Rodent behavior following a dural inflammation model with anti-CGRP migraine medication treatment
por: Reducha, Philip V., et al.
Publicado: (2023) -
CGRP and Migraine: What Have We Learned From Measuring CGRP in Migraine Patients So Far?
por: Kamm, Katharina
Publicado: (2022) -
New Anti-CGRP Medications in the Treatment of Vestibular Migraine
por: Hoskin, Justin L., et al.
Publicado: (2022) -
The Vasodilatory Response to CGRP of the Anterior and Posterior Cerebral Circulation in Migraine
por: Visočnik, Darja, et al.
Publicado: (2022) -
Cross-talk signaling in the trigeminal ganglion: role of neuropeptides and other mediators
por: Messlinger, Karl, et al.
Publicado: (2020)